103 related articles for article (PubMed ID: 16257153)
1. Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin.
Rodríguez-Ibáñez M; Sánchez-Castaño G; Montalar-Montero M; Garrigues TM; Bermejo M; Merino V
Int J Pharm; 2006 Jan; 307(1):33-41. PubMed ID: 16257153
[TBL] [Abstract][Full Text] [Related]
2. In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation with in vitro results.
González-Alvarez I; Fernández-Teruel C; Casabó-Alós VG; Garrigues TM; Polli JE; Ruiz-García A; Bermejo M
Biopharm Drug Dispos; 2007 Jul; 28(5):229-39. PubMed ID: 17410527
[TBL] [Abstract][Full Text] [Related]
3. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies.
Rodríguez-Ibáñez M; Nalda-Molina R; Montalar-Montero M; Bermejo MV; Merino V; Garrigues TM
Eur J Pharm Biopharm; 2003 Mar; 55(2):241-6. PubMed ID: 12637104
[TBL] [Abstract][Full Text] [Related]
4. Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells.
Fernandez-Teruel C; Gonzalez-Alvarez I; Casabó VG; Ruiz-Garcia A; Bermejo M
J Drug Target; 2005 Apr; 13(3):199-212. PubMed ID: 16036308
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro.
Zakelj S; Sturm K; Kristl A
Int J Pharm; 2006 Apr; 313(1-2):175-80. PubMed ID: 16529884
[TBL] [Abstract][Full Text] [Related]
6. Unique pharmacology of KAR-2, a potential anti-cancer agent: absorption modelling and selective mitotic spindle targeting.
Gonzalez-Alvarez I; Gonzalez-Alvarez M; Oltra-Noguera D; Merino V; Tõkési N; Ovádi J; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):11-9. PubMed ID: 19028571
[TBL] [Abstract][Full Text] [Related]
7. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5.
Arakawa H; Shirasaka Y; Haga M; Nakanishi T; Tamai I
Biopharm Drug Dispos; 2012 Sep; 33(6):332-41. PubMed ID: 22899169
[TBL] [Abstract][Full Text] [Related]
8. PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones.
Bermejo M; Avdeef A; Ruiz A; Nalda R; Ruell JA; Tsinman O; González I; Fernández C; Sánchez G; Garrigues TM; Merino V
Eur J Pharm Sci; 2004 Mar; 21(4):429-41. PubMed ID: 14998573
[TBL] [Abstract][Full Text] [Related]
9. Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models.
Berggren S; Hoogstraate J; Fagerholm U; Lennernäs H
Eur J Pharm Sci; 2004 Mar; 21(4):553-60. PubMed ID: 14998587
[TBL] [Abstract][Full Text] [Related]
10. Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
Lowes S; Simmons NL
Br J Pharmacol; 2002 Mar; 135(5):1263-75. PubMed ID: 11877335
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.
Gontijo AV; Brillault J; Grégoire N; Lamarche I; Gobin P; Couet W; Marchand S
Antimicrob Agents Chemother; 2014 Jul; 58(7):3942-9. PubMed ID: 24798283
[TBL] [Abstract][Full Text] [Related]
12. Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models.
Xu YA; Fan G; Gao S; Hong Z
Drug Dev Ind Pharm; 2008 Feb; 34(2):164-70. PubMed ID: 18302035
[TBL] [Abstract][Full Text] [Related]
13. Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat.
Muñoz MJ; Merino-Sanjuán M; Lledó-García R; Casabó VG; Máñez-Castillejo FJ; Nácher A
Eur J Pharm Biopharm; 2005 Sep; 61(1-2):20-6. PubMed ID: 16005197
[TBL] [Abstract][Full Text] [Related]
14. Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H; Yano I; Saito H; Inui K
Pharm Res; 2004 Feb; 21(2):330-8. PubMed ID: 15032316
[TBL] [Abstract][Full Text] [Related]
15. Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier.
Simon Z; Katja B; Darko U; Marjan V; Albin K
J Pharm Biomed Anal; 2010 Nov; 53(3):655-9. PubMed ID: 20643295
[TBL] [Abstract][Full Text] [Related]
16. Permeability evaluation of peptidic HCV protease inhibitors in Caco-2 cells-correlation with in vivo absorption predicted in humans.
Li C; Liu T; Broske L; Brisson JM; Uss AS; Njoroge FG; Morrison RA; Cheng KC
Biochem Pharmacol; 2008 Dec; 76(12):1757-64. PubMed ID: 18835257
[TBL] [Abstract][Full Text] [Related]
17. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
18. Involvement of multidrug resistance-associated protein 2 in intestinal secretion of grepafloxacin in rats.
Naruhashi K; Tamai I; Inoue N; Muraoka H; Sai Y; Suzuki N; Tsuji A
Antimicrob Agents Chemother; 2002 Feb; 46(2):344-9. PubMed ID: 11796340
[TBL] [Abstract][Full Text] [Related]
19. In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model.
Lozoya-Agullo I; González-Álvarez I; González-Álvarez M; Merino-Sanjuán M; Bermejo M
J Pharm Sci; 2015 Sep; 104(9):3136-45. PubMed ID: 25891783
[TBL] [Abstract][Full Text] [Related]
20. Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat.
Dahan A; West BT; Amidon GL
Eur J Pharm Sci; 2009 Feb; 36(2-3):320-9. PubMed ID: 19028572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
